Health Care · Biological Products, (No Diagnostic Substances)

PLX Protalix BioTherapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1006281141 filings
Russell 2000

PLX at a glance

Protalix BioTherapeutics, Inc. (PLX, SEC CIK 1006281) filed its latest 10-K annual report on March 18, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as September 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Protalix BioTherapeutics, Inc. (PLX) reported revenue of $52.7 million (down 1.2% from FY2024) and a net loss of $6.6 million. Diluted EPS was -$0.08.
  • As of September 30, 2026, 21 institutional investment managers tracked by SignalX reported holding Protalix BioTherapeutics, Inc. (PLX) shares worth $28.8 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$52.7M
−1.2% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
21 funds
$28.8M · −3 vs prior quarter
Latest 8-K
Nov 10, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to previously disclosed risk factors in the 2025 Form 10-K
  • No material changes to risk factors reported in the June 30, 2026 Form 10-Q

Management Discussion & Analysis

  • Q3 revenue $21.925M, up from $17.851M YoY, driven by selling-goods revenue of $21.834M
  • Q3 operating margin 18.5% vs 11.9% YoY, with operating income $4.047M vs $2.131M
  • Best segment Chiesi, Q3 sales $13.138M vs $8.763M; worst Fiocruz, $4.365M vs $6.105M
  • Cash and short-term deposits $48.5M; nine-month operating cash flow $15.529M vs $(14.023)M YoY
  • Management expects rising R&D spending for the RELEASE study, with funds sufficient for at least 12 months

AI summary of the PLX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 10, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $21.9M and net income $4.0M, up from $17.9M and $2.4M year over year
  • Nine-month revenue $75.6M, including $25.0M Chiesi milestone, versus $43.6M in 2025

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Protalix’s quarter ended September 30, 2026
  • Business and clinical updates accompany the quarterly financial results
Filed Aug 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 fiscal 2026 results covered quarter ended June 30, 2026
  • Business and clinical update accompanied financial results

Item EX-99.1: Item EX-99.1

  • Q2 revenue $19.9M, up from $15.7M, with product sales rising to $19.8M on stronger Elfabrio demand
  • Six-month revenue $53.6M included a $25.0M Chiesi milestone, making recurring commercial revenue quality especially important
Filed Jun 25, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • Stockholders elected all eight director nominees, maintaining board continuity; Amos Bar Shalev received the highest withheld vote count at 6,461,724
  • Executive compensation approved on advisory basis, with 28,368,614 votes for and 6,683,937 against

AI summaries of PLX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for PLX

Don't miss the next PLX filing

  • Alerts as it files. A push when PLX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut PLX, by share count.
  • Ask anything. An AI agent that reads every PLX filing and answers with sources.

PLX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Elze ChristianASep 3, 2026-
Elze ChristianASep 3, 2026-
Ben Zvi ShmuelASep 3, 2026-
Ben Zvi ShmuelASep 3, 2026-
Forster EliotASep 3, 2026-
Forster EliotASep 3, 2026-
Melincoff Gwen AASep 3, 2026-
Melincoff Gwen AASep 3, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$53.4M$52.7M
Operating Income$10.5M$3.9M-$5.5M
Net Income$8.3M$2.9M-$6.6M
Op. Margin-7.3%-10.4%
Net Margin-5.5%-12.5%
Balance Sheet
Total Assets$84.4M$73.4M$82.3M
Equity-$43.2M$48.2M
ROE-6.8%-13.7%
Per Share
EPS$0.09$0.04$-0.08
Cash Flow
Operating CF-$8.7M-$12.0M
CapEx-$1.3M$1.6M

Source: XBRL data in Protalix BioTherapeutics, Inc. (PLX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate PLX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
PLX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202621$28.8M
Q2 202624$23.2M
Q1 202621$18.5M
Q4 202519$14.6M
Q3 202518$16.4M
Q2 202517$11.9M
Q1 202511$8.8M
Q4 20245$4.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 136 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

PLX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 10, 2026Analysis-
10-QNov 10, 2026Analysis
4Sep 9, 2026--
4Sep 4, 2026--
4Sep 4, 2026--
4Sep 4, 2026--
4Sep 4, 2026--
4Sep 4, 2026--
4Sep 4, 2026--
4Sep 4, 2026--
4Sep 4, 2026--
10-QAug 12, 2026Analysis
8-KAug 12, 2026Analysis-
SC 13GJul 29, 2026-
8-KJun 25, 2026Analysis-
8-KMay 21, 2026Analysis
8-KMay 13, 2026Analysis
10-QMay 13, 2026Analysis
8-KMar 18, 2026Analysis-
10-KMar 18, 2026-
8-KMar 9, 2026Analysis-
SC 13GMar 4, 2026-
8-KFeb 11, 2026-
8-KJan 30, 2026-
8-KJan 5, 2026-

Related Health Care companies

All Health Care →

PLX SEC filings: frequently asked questions

Which institutions hold PLX stock?

As of September 30, 2026, the largest Protalix BioTherapeutics, Inc. (PLX) holders among the 13F filers tracked by SignalX were BlackRock ($11.6 million), State Street Corp ($3.2 million), Renaissance Technologies LLC ($2.7 million), Goldman Sachs Group ($2.5 million), Northern Trust ($2.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was PLX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Protalix BioTherapeutics, Inc. (PLX) reported revenue of $52.7 million (down 1.2% from FY2024) and a net loss of $6.6 million. Diluted EPS was -$0.08. The figures come from the XBRL data in the 10-K.

What did PLX report in its latest 8-K?

Protalix BioTherapeutics, Inc. (PLX) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $21.9M and net income $4.0M, up from $17.9M and $2.4M year over year.

What are the latest PLX SEC filings?

Protalix BioTherapeutics, Inc. (PLX) filed its latest 10-K annual report on March 18, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on September 9, 2026.

What is PLX's SEC CIK number?

Protalix BioTherapeutics, Inc. (PLX)'s SEC Central Index Key (CIK) is 1006281. EDGAR lists every PLX filing under that number.

Ask anything about PLX

The research agent reads PLX's filings, financials, insider trades and 13F holders, then answers with sources.